Pharmaceutical Business review

Breckenridge signs LOI with IDL

Under the terms of this letter of intent (LOI), IDL will develop and manufacture the product which will be marketed and distributed by Breckenridge.

The two companies plan to file an abbreviated new drug application with the FDA in early 2009.